The company's technology, called CONFO®, stabilizes G-protein coupled receptors (GPCRs) in a specific conformation, allowing for the discovery of novel agonists for better therapeutic intervention. Confo Therapeutics is building a portfolio of programs based on this technology, which derives specialized camelid single-domain antibodies. These antibodies stabilize GPCRs in a conformation of interest for drug discovery, providing the medical industry with novel pathway-selective agonists for improved therapeutic intervention.